Eisai receives approval for ACIPHEX Sprinkle.
M2 PHARMA-March 29, 2013-Eisai receives approval for ACIPHEX Sprinkle(C)2013 M2 COMMUNICATIONS
Eisai (TYO: 4523), a Japan-based pharmaceutical company, has received approval from the US FDA for ACIPHEX Sprinkle as a 12-week gastroesophageal reflux disease therapy for use in children between one to eleven years of age.
It was reported yesterday that the company has received the approval based on positive data from a multi-centre, double-blind trial conducted in 127 paediatric patients between one to 11 years of age with gastroesophageal reflux disease.
The parallel-group study included a treatment period of 12 weeks and an extension period of two dose levels of rabeprazole for 24 weeks.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 29, 2013|
|Previous Article:||Vetter Pharma's new centre for visual inspection and logistics passes first GMP inspection.|
|Next Article:||Dr Reddya[euro](tm)s Shares Gain on US Announcement.|